Keyphrases
5-year Survival
33%
Advanced Stage
100%
Aggressive Treatment
33%
Clinical Features
33%
Clinical Outcomes
33%
Frequent Relapses
33%
Initial Diagnosis
33%
Initial Treatment
33%
Locoregional
33%
Locoregional Recurrence
33%
Long-term Survival
33%
Lymph Node
33%
Lymphoid Organs
33%
Marginal Zone Lymphoma
100%
Median Time
66%
Mucosa-associated Lymphoid Tissue
33%
Non-gastric
100%
Ocular Adnexa
33%
Overall Response Rate
33%
Overall Survival
33%
Prolonged Survival
33%
Relapsed or Refractory
100%
Relapsed Patients
33%
Retrospective Analysis
100%
Salvage Treatment
33%
Site of Involvement
33%
Survival Duration
33%
Time to Progression
66%
Time to Relapse
33%
Working Diagnosis
33%
Medicine and Dentistry
Adnexa
50%
Clinical Feature
50%
Lymph Duct
50%
Lymph Node
50%
MALT Lymphoma
100%
Mucosa-Associated Lymphoid Tissue
50%
Overall Survival
100%
Recurrent Disease
50%
Immunology and Microbiology
Lymph Node
50%
Marginal Zone B-Cell
100%
Mucosa-Associated Lymphoid Tissue
50%
Overall Survival
100%
Neuroscience
B Cell
100%
Lymph Node
50%
Lymphatic Tissue
50%
Mucous Membrane
50%